Results 81 to 90 of about 2,404 (154)

Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available.
Hsin-Chweng Lien, Chi-Hone Lien, Tzu-Yu Liu, Shun-Long Weng, Yu-Lin Tai, Ya-Ning Huang, Hsin Chi, Nan-Chang Chiu, Chun-Yan Yeung, Chien-Yu Lin   +9 more
doaj   +1 more source

The Efficacy and Safety of Nirsevimab in the Prevention of RSV Related Infections in Healthy Infants [PDF]

Objective: To assess the efficacy and safety of preventing Respiratory Syncytial virus (RSV) related respiratory illnesses and hospitalization with the use of Nirsevimab, as compared to placebo among infants among healthy early and late preterm infants ...
Mayo, Gabrielle, Ballard, Suyin
core  

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States

Vaccines
Background/Objectives: Respiratory syncytial virus (RSV) causes a significant hospitalization burden in infants. The objective of this study was to evaluate the cost-effectiveness of introducing clesrovimab, a recently approved long-acting monoclonal ...
Klodeta Kura, John C. Lang, Dawei Wang, Yoonyoung Choi, Michelle G. Goveia, Anushua Sinha, Yao-Hsuan Chen, Elamin H. Elbasha   +7 more
doaj   +1 more source

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024 [PDF]

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC\u27s Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants ...
Boom, Julie A, Toepfer, Ariana P, Goldstein, Leah, Clopper, Benjamin R, Dawood, Fatimah S, Englund, Janet A, Sahni, Leila C, Schlaudecker, Elizabeth P, Albertin, Christina, Zerr, Danielle M, Schuster, Jennifer E, Michaels, Marian G, Betters, Kristina A, Rohlfs, Chelsea, Stewart, Laura S, Halasa, Natasha B, Selvarangan, Rangaraj, Piedra, Pedro A, McKeever, Erin R, McMorrow, Meredith L, Klein, Eileen J, Musa, Samar, Tannis, Ayzsa, Moline, Heidi L, Staat, Mary Allen, Williams, John V, Weinberg, Geoffrey A, Szilagyi, Peter G, Kalman, Casey, Banerjee, Dithi   +29 more
core   +1 more source

Nirsevimab (▼Beyfortus®): un nuevo anticuerpo monoclonal para la profilaxis frente al virus respiratorio sincitial [PDF]

, 2023
Farmacologia; Medicaments; Virus respiratori sincicialFarmacología; Medicamentos; Virus respiratorio sincicialPharmacology; Medicines; Respiratory syncytial virusAquest article tracta del medicament nirsevimab, un nou anticòs monoclonal que actua ...

core  

Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study

Infectious Diseases and Therapy
Introduction Germany’s Standing Committee on Vaccination (STIKO) recommends the use of monoclonal antibody nirsevimab for infants in their first respiratory syncytial virus (RSV) season; however, incorporating RSVpreF maternal vaccination may protect ...
Caroline Lade, Erin Quinn, Lea J. Bayer, Amy W. Law, Christof von Eiff, Julia Schiffner-Rohe, Mark Atwood, Bennet Huebbe, Ahuva Averin   +8 more
doaj   +1 more source

Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season

Vaccines
Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden, particularly in newborns and infants during their first year of life.
Alessandra Consolati, Mariapaola Farinelli, Paolo Serravalle, Christine Rollandin, Laura Apprato, Susanna Esposito, Salvatore Bongiorno   +6 more
doaj   +1 more source

Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study

International audienceBackgroundNirsevimab, a long-acting monoclonal antibody, has been approved for the prevention of respiratory syncytial virus (RSV) infection in infants.
Morton Fauche, Claire, Derman, Boris, Azemar, Benjamin, Guinard, Jérome, Yab, Emilie, Reslan, Alawyia, Mouna, Lina, Gras-Le Guen, Christele, Flechelles, Olivier, Dossou, Nefert Candace, Brichler, Ségolène, Jatteau, Pierre, Rahou, Yannis, Calvez, Vincent, dos Santos, Georges, Gabassi, Audrey, Fourati, Slim, Plantier, Jean-Christophe, Prot, Matthieu, Legros, Romain, Moreau, Frédérique, Cantais, Aymeric, Bouthry, Elise, Crémadés, Agathe, Gault, Elyanne, Francois, Catherine, Cocherie, Théophile, Boussetta-Charfi, Oulfa, da Silva, Kévin, Schnuriger, Aurélie, Salmona, Maud, Thibault, Vincent, Zemali, Nael, Gaymard, Alexandre, Mnemosyme, Nicolas, Mortamet, Guillaume, Pronier, Charlotte, Bal, Antonin, Bret, Laurent, Avettand-Fenoel, Véronique, Gaitan, Léa, Pawlotsky, Jean-Miichel, Soulié, Cathia, Gallais, Floriane, Bourlet, Thomas, Carcenac, Romain, Simon-Loriere, Etienne, Schwartz, Olivier, Le Goff, Jérôme, Natella, Pierre-André, Staes, Laetitia, Handala, Lynda, Lemoine, Frédéric, Fagour, Laurence, Moisan, Alice, Rogez, Sylvie, Lemoine, Frédérique, Fofana, Djeneba, Ly, Arnaud, Tournegros, Caroline, Rodallec, Audreay, Rachik Abdeljalil, Senhaji, Henry, Steven, Hartard, Cédric, Castain, Louise, Claudet, Isabelle, Audureau, Etienne, Ferrani, Salim, Vallet, Sophie, Castelain, Sandrine, Jeziorski, Eric, Lefeuvre, Caroline, Buchrieser, Julian, Pillet, Sylvie, Veyrenche, Nicolas, Henquell, Cecile, Burrel, Sonia, Mafi, Sarah, Lesne, Fabien, Warnakulasuriya, Fairly, Pilorgé, Léa, Guillaume, Clémence, Jaffar, Marie-Christine, de Pontual, Loic, Bonacorsi, Stéphane, Petat, Hortense, Domitien, Léa, Ader, Mohamed, Regueme, Alexandre, Teyssou, Elisa, Bourret, Jérome, Ouldali, Naim, Foulongne, Vincent, Berreira Ibraim, Samar, Marie, Victoria, Rames, Cinthia, Pawlotsky, Jean-Michel, Tremeaux, Pauline, Enouf, Vincent, Schapira, Anne-Julie, Henry, Amandine, Zekre, Franck, Leveque, Nicolas, Heaugwane, Diana, Rodriguez, Christophe, Zavaoarisaina, Zakasoa-Mbololona, Gaudy-Graffin, Catherine, Vellas, Camille, Perrier, Marine, Néré, Marie-Laure, Vabret, Astrid, Chenafi-Adham, Sara, Le Hingrat, Quentin, Ogoudjobi, Stanislas, Solis, Morgane, Alidjinou, Kazali, Engelmann, Ilka, Rameix-Welti, Marie-Anne, Habib, Mohamed, Marot, Stéphane, Mchantaf, Gilbert, de Oliveira, Anthony, Faisant, Anne, Imbert-Marcille, Berthe-Marie, Gleizes, Eva, Donati, Flora, Deback, Claire, Deroche, Luc, Jeyarajah, Banujaa, Pucelle, Mélanie, Sourice, Justine, Jaffar-Bandjee, Marie-Christine, Soulier, Alexandre, Seng, Sarah, Reslan, Alawiya, Larrat, Sylvie, Souply, Laurent, Pennisi, Alessandra, Kombou, Jose, Aupiais, Camille, Pargny, Vincent, Mirand, Audrey, Cappy, Pierre, Chollet, Lionel, Chauvire-Drouard, Anne, Gardan, Vincent, Bécourt, Arnaud, Casalegno, Jean-Sébastien, Stephan, Valentin, Imbert, Berthe-Marie   +149 more
core   +1 more source

CDC\u2019s Vaccines for Children Program Addendum : Special Considerations for Nirsevimab

Nirsevimab is an FDA-licensed monoclonal antibody that provides passive immunity against RSV-associated infection. On August 3, 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend nirsevimab as an immunization for all infants

core  

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost–utility modelling study

BMJ Public Health
Introduction Respiratory syncytial virus (RSV) causes great morbidity and mortality among newborns. Nirsevimab represents a prophylactic alternative used in Spain for a universal prophylaxis strategy of all infants.
Miguel Angel Casado, Ruth Gil-Prieto, Jaime Pérez-Martín, Ariadna Díaz Aguiló, Samira Soudani, Leticia Platero-Alonso, Juan Luis López-Belmonte, Alberto de la Cuadra-Grande, Javier Álvarez Aldean   +8 more
doaj   +1 more source